AINDEX
Markets

Molecular Partners AG (MOLN)

MOLNNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)

$2.86

+0.1614 (+5.98%) today

Closed, Nov 17, 4:00 PM ET

+5.98% 1D
Market cap
$103.91m
P/E
–
EPS, last 4 quarters
$-1.68
Dividend yield
–
Day range
–
52-week range
$2.63 to $5.36
Average volume
–
Previous close
$2.70

Analysts

3 covering

Buy3 buy, 0 hold, 0 sell

Targets a year out average $11.00, +284.6% from here

$8.00now $2.86$13.00

Earnings

next estimate $-0.4400

Next report

Dec 2025

-7.9%

Mar 2026

-18.4%

Jun 2026

+2.2%

Sep 2026

+17.4%

estimate reported, and the surprise

Financials

QuarterMar 2021
Revenue$1.04m
Gross profit$1.04m
Operating income-$19.69m
Net income-$17.59m

News

8 latest

The company

Molecular Partners AG (SIX, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of medicines known as DARPin therapeutics for cancer patients underserved by existing treatment modalities. Molecular Partners focuses on the development of targeted radiotherapeutics, leveraging the unique properties of DARPin miniproteins as isotope-agnostic vector. The Company's lead medicine MP0712, targeting DLL3 and armed with 212Pb, advances in a US multicenter Phase 1/2a study for patients with small cell lung cancer and other neuroendocrine cancers (NCT07278479). Molecular Partners has established partnerships with industry leaders and academic centers covering the full value chain of radiotherapeutics. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ-GS
Region
Europe

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.